UK & Europe

Real-world data from nearly 4,000 European type 1 diabetes patients shows Kaleido met consensus time-in-range targets with median hypoglycaemia of just

The EMA has begun its centralised review of lorecivivint, a small-molecule CLK/DYRK inhibitor Biosplice positions as a potential first disease-modifying therapy for

The Amsterdam biotech reported a 38% rise in active methotrexate inside immune cells, supporting a €10m Series A and a Phase 2a trial in 2027.

Novo Nordisk presented STEP UP sub-analysis at EASD 2026 showing Wegovy reduced mean liver fat from 8.8% to 3.1% over 72 weeks

Four next-generation long-acting antibodies targeting IL-13, IL-4 and IL-4Rα join the partnership that produced Dupixent, with Regeneron receiving $1bn upfront.

The EMA has accepted PolyPid's marketing authorisation application for D-PLEX100, which also faces an FDA PDUFA date of 28 November 2026.

Phase III evERA data published in NEJM show giredestrant plus everolimus nearly halved disease progression risk in ER-positive advanced breast cancer.

Boehringer Ingelheim's glucagon/GLP-1 dual agonist met both co-primary endpoints in SYNCHRONIZE-2, with full results published simultaneously in the New England

SYNCHRONIZE-2 showed 13.1% average weight loss versus 3.1% on placebo after 76 weeks, with significant glycaemic improvements published in the NEJM.

Egle's IL-2 agonist EGL-003 was well tolerated across four dose cohorts and produced selective Treg expansion, supporting a Q4 2026 atopic dermatitis

New EASD 2026 data show CagriSema modifies brain food-cue responses and reduces ectopic fat, with bone health maintained during weight loss.

Highlight Therapeutics' intralesional BO-112 met its primary visual and pathological response endpoint in 61% of basal cell carcinoma patients.

ZUPREME-1 Phase 2 results, published in The Lancet, show petrelintide cut body weight by up to 10.7% with placebo-comparable GI tolerability.

Novo Nordisk will pay $300m upfront for global rights to HRS-1596, a once-weekly oral dual GLP-1/GIP agonist nearing Phase 1 trials.

Belite Bio will present topline Phase 3 results for tinlarebant in adolescent Stargardt disease at Euretina in Vienna, ahead of a February 2027 FDA PDUFA

IBA has signed a contract with Rome's IFO to deliver a Proteus ONE proton therapy system, bringing gantry-based treatment to central and southern

Oryzon Genomics has received EMA authorisation to begin a Phase IIa study of vafidemstat in Phelan-McDermid Syndrome, a rare autism-linked genetic disorder with

Addex reported a net loss of CHF 3.5m for the first half of 2026, with cash at CHF 0.8m after an ATM raise

The Dijon-based emergency-medicine biotech returned to positive equity after a €15m capital raise, with its BARDA contract now extended through 2030.

The German pharma group will contribute $5 million over three years to strengthen obesity and metabolic health systems in resource-limited settings.